Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STN1014200
- Development stage
- Phase 3
- Lead developer
- Cloudbreak Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
STN1014200 (also known as CBT-001) is an ophthalmic emulsion formulation of nintedanib, a potent multi-tyrosine kinase inhibitor. Developed by Santen Pharmaceutical in collaboration with Cloudbreak Therapeutics, it is primarily being investigated for the treatment of pterygium, a benign growth of the conjunctiva that can extend onto the cornea. The drug works by inhibiting key signaling pathways involved in angiogenesis and fibrosis, specifically targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). By blocking these receptors, STN1014200 aims to reduce the vascularity and growth of pterygium lesions, potentially providing a non-surgical therapeutic option for patients. It is currently in Phase 2 clinical development in Japan.
- Other names
- nintedanib ophthalmic emulsion
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on STN1014200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STN1014200.